CervoMed Inc.
June 16, 2025
Company Presentation
Brain Health
153B
CervoMed is a clinical-stage company that is a leader in developing a disease modifying treatment for dementia with Lewy bodies (DLB), the 3rd most common chronic neurodegenerative disorder, trailing only Alzheimer's and Parkinson's disease. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying specific neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. In March 2025, CervoMed reported 16-week results from the extension phase of the 159-patient RewinD-LB phase 2b clinical trial that demonstrated clinical proof-of-concept for neflamapimod as a treatment for DLB. The Company plans to initiate a Phase 3 trial in DLB in mid-2026, following a meeting with the FDA and subject to available funding.
Company HQ City:
Boston
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2014; public since August 2023
Lead Product in Development:
Neflamapimod
CEO
John J. Alam, MD
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
Exchange
NASDAQ
Ticker
CRVO
When you expect your next catalyst update?
Meeting with FDA to confirm phase 3 plans, and then initiate phase 3 in mid-2026
What is your next catalyst (value inflection) update?
Late 2025/Early 2026
Website
https://www.cervomed.com/
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}